Target intelligence / Profile preview

Proteasome 26S subunit, non-ATPase 14 (PSMD14)

Target
PSMD14
Molecular classification
Enzyme (metalloprotease, deubiquitinase), Proteasome regulatory subunit, Proteasome (large multi-protein complex) component
01

Overview

Proteasome 26S subunit, non-ATPase 14 (PSMD14) is a zinc-dependent metalloprotease and a critical deubiquitinating enzyme within the 19S regulatory particle of the 26S proteasome, responsible for removing polyubiquitin chains from targeted substrates prior to their degradation by the proteasome’s 20S core. This function is essential for regulated protein turnover, cellular homeostasis, and quality control. PSMD14 specifically recognizes and cleaves Lys-63-linked ubiquitin chains and thereby regulates diverse cellular processes, including cell cycle progression, apoptosis, DNA double-strand break repair, and multiple oncogenic signaling pathways. Aberrant activity or expression of PSMD14 has been implicated in cancer progression, multidrug resistance, and neurodegenerative disorders. While PSMD14 is considered a promising therapeutic target—especially for certain cancers—no selective, clinically approved inhibitors exist as of 2024, and broad proteasome inhibition can lead to significant toxicity due to interference with essential cellular protein degradation

Other names
26S proteasome non-ATPase regulatory subunit 1426S proteasome regulatory subunit Rpn11POH1PAD1RPN11proteasome (prosome, macropain) 26S subunit, non-ATPase, 14testis tissue sperm-binding protein Li 69n
02

Mechanism of action

Inhibition of PSMD14’s deubiquitinase (metalloprotease) activity prevents deubiquitination and leads to accumulation of polyubiquitinated proteins, impaired proteasomal degradation, cell cycle arrest, and apoptosis, with anti-tumor effects in preclinical models

03

Biological functions

Protein degradation (ubiquitin-proteasome system)Regulation of protein homeostasisDNA damage response and repairRegulation of cell cycleApoptosisRegulation of oncogenic signaling pathways
04

Disease associations

Cancer (e.g. liver, breast, melanoma, tumor progression)Cystic fibrosisMachado-Joseph diseaseNeurodegenerative diseases
05

Safety considerations

Potential for broad disruption of protein homeostasis, leading to toxicity in non-cancerous dividing tissuesPossible hematological toxicity, peripheral neuropathy, and off-target effects analogous to proteasome inhibitor class effects
06

Interacting drugs

Capzimin (selective PSMD14 inhibitor, research compound)

2 more in the full profile.

07

Biomarkers

Protein expression level (for research: association with aggressiveness in specific cancers, e.g. melanoma, liver cancer)No established, clinically validated biomarkers for patient selection as of 2024

Beyond the preview

Go deeper on Proteasome 26S subunit, non-ATPase 14 (PSMD14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome 26S subunit, non-ATPase 14 (PSMD14).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call